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ABSTRACT
BRCA1/2 mutations are significant risk factors for hereditary breast and ovarian 
cancer (HBOC), its mutation frequency in HBOC of Chinese ethnicity is around 9%, in 
which nearly half are recurrent mutations. In Hong Kong and China, genetic testing 
and counseling are not as common as in the West. To reduce the barrier of testing, 
a multiplex SNaPshot genotyping panel that targeted 25 Chinese BRCA1/2 mutation 
hotspots was developed, and its feasibility was evaluated in a local cohort of 441 
breast and 155 ovarian cancer patients. For those who tested negative, they were 
then subjected to full-gene testing with next-generation sequencing (NGS). BRCA 
mutation prevalence in this cohort was 8.05% and the yield of the recurrent panel 
was 3.52%, identifying over 40% of the mutation carriers. Moreover, from 79 Chinese 
breast cancer cases recruited overseas, 2 recurrent mutations and one novel BRCA2 
mutation were detected by the panel and NGS respectively. The developed genotyping 
panel showed to be an easy-to-perform and more affordable testing tool that can 
provide important contributions to improve the healthcare of Chinese women with 
cancer as well as family members that harbor high risk mutations for HBOC.
INTRODUCTION
Breast cancer is the most common cause of cancer 
mortality in women worldwide and in Asia. In Hong Kong, 
breast cancer accounts for 26.6% of all newly diagnosed 
cancers and 10.8% of all cancer deaths in females in 2014 
[1]. It is predicted that, based on the present trend, there 
will be an exponential increase in breast cancer incidence 
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in Hong Kong and other Asian countries, particularly 
China. The fact that inhabitants of Asian countries 
comprise 60% of the world’s population has significant 
implications for public health planning in the region.
Hereditary breast and ovarian cancer syndrome 
(HBOC) is an inherited genetic disease, of which BRCA1 
and BRCA2 gene mutations are a prevalent cause. About 
10% of the breast cancer cases in Hong Kong are inherited 
[2], and BRCA mutation carriers have a higher risk of 
developing breast cancer (45-65%) or ovarian cancer (11-
39%) by the age of 70 than those without a BRCA mutation. 
The prevalence and risk management for BRCA carriers 
were addressed by previous pre-clinical and clinical studies, 
resulting in recommendations for screening and risk-
reduction intervention for BRCA carriers and their family 
members. Surveillance of women with BRCA mutations 
include annual MRI breast screening from the age of 25 
years alternating with mammography screening (National 
Comprehensive Cancer Network guidelines). Preventive 
alternatives include taking endocrine risk reducing drugs 
(tamoxifen or raloxifene) for five years, or risk-reducing 
mastectomy and salpingo-oophorectomy. The latter have 
been shown to reduce the risks of breast and ovarian 
cancers by 90% and 85% respectively. Risk reducing 
prophylactic salpingo oophorectomy is also associated with 
reduced overall mortality rates in BRCA mutation carriers 
[3–5]. BRCA mutation carriers among triple negative 
breast cancer (TNBC) patients are more likely to benefit 
from platinum-based chemotherapeutic agents [6]. A new 
emerging class of poly ADP-ribose polymerase (PARP) 
inhibitors, such as olaparib and rucaparib, also showed 
promising responses for ovarian cancer patients with BRCA 
defects in delaying disease progression and extending time 
to subsequent chemotherapy in a metastatic setting [7]. 
Hence, determination of BRCA mutation status is becoming 
important for clinical management with the emerging 
data supporting its use in therapy decisions. Also, genetic 
counselling and clinical interventions can be offered to 
family members of the affected patients.
To date, thousands of different mutations have 
been identified in BRCA1 and BRCA2 genes. However, 
specific BRCA1/2 recurrent mutations were more 
commonly seen in different ethnic groups due to 
founder effect. For example, three well-characterized 
founder mutations (BRCA1 c.68_69delAG, c.5266dupC 
and BRCA2 c.5946delT) account for majority of the 
mutations identified in Ashkenazi Jews, and was reported 
to have a frequency of about 2.6% in the population 
[8–10]. In China, increasing trends in breast cancer 
incidence and mortality were observed, with about 
270,000 new cases in 2015 [11]. Several recurrent 
and founder mutations have been reported in Chinese 
populations from different geographic locations, examples 
are BRCA1 c.981_982delAT and c.5470_5477del 
ATTGGGCA in Eastern China [12], BRCA2 c.3109C>T, 
c.7436_7805del370 and c.9097dupA in Hong Kong [13].
Although next-generation sequencing (NGS) 
platforms have become more popular for multi-gene 
panel testing [2], it is not readily accessible in most of 
the clinical laboratories due to limited resources, the need 
for bioinformaticians and data analysis of sequencing 
data. In the present study, we describe the development 
of a multiplexed, SNaPshot primer extension genotyping 
assay, which allows the rapid and cost-effective detection 
of targeted BRCA1 and BRCA2 mutations from breast and 
ovarian cancer patients in Chinese populations.
RESULTS
Patient and tumor characteristics
Based on the local data on BRCA1/2 mutation 
spectrum and in combination with literature search, we 
selected 25 Chinese recurrent mutations at 13 BRCA1 loci 
and 12 BRCA2 loci (Table 1) and developed the SNaPshot 
genotyping panel. The panel was used to screen BRCA 
mutation in local Chinese cohorts of 441 breast cancer 
and 155 ovarian cancer patients, and an overseas cohort 
of 79 breast cancer patients. To further demonstrate the 
feasibility of the SNaPshot genotyping panel in Chinese 
populations, we also collected information of BRCA1/2 
deleterious mutations from 84 overseas Chinese carriers.
A total of 441 local Chinese breast cancer probands 
were recruited based on the high-risk selection criteria. 
The mean age of diagnosis was 47.11 years with the range 
from 18-87 years. Of these, 84 patients (19.05%) had 
developed bilateral breast cancer. Majority of the tumors 
(60.19%) were invasive ductal carcinoma (IDC, n=316) 
while 15.81% were ductal carcinoma in situ (DCIS, n=83). 
The histology of the tumors were shown in Table 2, 332 
(63.24%) were ER+, 44 (8.38%) were HER2+ and 59 
(11.24%) were triple-negative.
In the unselected cohort of 155 ovarian cancer 
probands (Table 3), the mean age of diagnosis was 
44.74 years with the range from 9-85 years, of whom 
139 probands had ovarian cancers (94.56%), others had 
fallopian tube cancer (1.36%) and peritoneal cancer 
(2.04%). The vast majority (n=138, 89.03%) of patient 
population had epithelial ovarian tumors, in which the 
most common histological subtype was endometrioid 
carcinoma (n=50, 32.26%), followed by serous (n=36, 
23.23%) and clear cell subtypes (n=24, 15.48%).
BRCA1/2 mutation status in local Chinese 
cohorts
All the probands were subjected to BRCA1/2 
mutational screening with the SNaPshot genotyping panel. 
For those who tested negative, they were further assayed 
for BRCA1/2 full-gene sequencing by amplicon-based 
NGS and large genomic rearrangements by multiplex 
ligation-dependent probe amplification (MLPA) (Figure 1). 
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The prevalence of BRCA1/2 pathogenic mutations among 
high-risk breast cancer patients was 7.94% (35/441). Of 
these, 4 BRCA1 and 11 BRCA2 mutation carriers were 
identified with the SNaPshot genotyping panel, showing 
a detection rate of 3.40% (15/441) among this cohort. 
Additionally, 5 BRCA1 and 15 BRCA2 mutations were 
identified by NGS/MLPA analysis. A great proportion of 
these BRCA carriers had family history of breast cancer 
(60%) compared with the non-carriers (40%) (p=0.013) 
(Table 2). There was a statistical difference regarding 
young onset ≤40 years (p=0.018) but not those ≤45 years 
(p=0.068) between the carriers and non-carriers.
Among the ovarian cancer patients, BRCA mutations 
were identified in 8.39% (13/155) of the patients, 
including 9 BRCA1 and 4 BRCA2. Of these, the SNaPshot 
genotyping panel identified 5 BRCA1 and 1 BRCA2 
carriers, showing a detection rate of 3.87% (6/155) among 
the cohort. Thirteen mutation carriers had a mean age at 
diagnosis of 53.6 years (range 37-85) and all had epithelial 
carcinoma, in which higher proportions were serous 
tumors (Table 3). Family history of breast/ovarian cancers 
is also a risk factor for detecting BRCA mutation between 
carriers (54.85%) and non-carriers (21.83%, p=0.017).
Overall, the prevalence of BRCA1/2 mutations 
in this highly selected local Chinese cohort was 8.05% 
(48/596) and the yield of the SNaPshot genotyping panel 
was 3.52% (21/596), indicating that nearly half of the 
mutations were recurrent mutations. BRCA1/2 mutations 
identified in this local Chinese HBOC cohort were 
listed in Table 4. Interestingly, we identified 3 BRCA1 
Table 1: List of frequently occurring BRCA1/2 pathogenic mutations identified in Chinese breast/ovarian cancer 
patients
Gene Nucleotide change Peptide change Exon/intron
BRCA1 c.470_471delCT p.Ser157* 8
c.964delG p.Ala322Leufs*19 11
c.981_982delAT p.Cys328* 11
c.2253_2254delGT p.Met751Ilefs*10 11
c.3333delA p.Glu1112Asnfs*5 11
c.3342_3345delAGAA p.Glu1115* 11
c.3916_3917delTT p.Leu1306Aspfs*23 11
c.4065_4068delTCAA p.Asn1355Lysfs*10 11
c.4148C>G p.Ser1383* 12
c.4372C>T p.Arg1443* 14
c.5406+1_5406+3delGTA p.Asp1778Glyfs*27 IVS22
c.5406+7A>G p.Asp1778Glyfs*27 IVS22
c.5470_5477del ATTGGGCA p.Ile1824Aspfs*3 24
BRCA2 c.1832C>A p.Ser611* 10
c.2595delA p.Glu866Lysfs*8 11
c.2808_2811delACAA p.Ala938Profs*21 11
c.3109C>T p.Gln1037* 11
c.4965delC p.Tyr1655* 11
c.5164_5165delAG p.Ser1722Tyrfs*4 11
c.6591_6592delTG p.Glu2198Asnfs*4 11
c.7007G>T p.Gly2313Alafs*31 13
c.7878G>A p.Trp2626* 17
c.8068_8069delGT p.Val2690Phefs*2 18
c.9097dupA p.Thr3033Asnfs*11 23
c.9294C>G p.Tyr3098* 25
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mutations (c.4046_4047delinsA, c.212+3A>G and 
c.5335delC) by NGS, which were novel to our Chinese 
BRCA1/2 mutation spectrum and were only seen in 
ovarian cancer cases, but not in the breast cancer cases in 
the present cohort.
All the BRCA1/2 mutations detected by SNaPshot 
genotyping panel and NGS were confirmed by independent 
Sanger sequencing, and the results were consistent. In 
addition, no false negative from the SNaPshot genotyping 
panel was seen, implicating the accuracy and feasibility 
of the panel.
BRCA1/2 mutation in overseas Chinese breast 
cancer patients
In the second part of this study, we collected 79 
blood samples from Chinese breast cancer probands 
residing in overseas countries including Australia, 
Table 2: Characteristics of 441 local Chinese breast cancer patients screened for BRCA1/2 mutations
441 tested probands 35 mutation carriers
Mean age at diagnosis 47.11 y 42.36 y
Age range 18 – 87 y 22 – 70 y
Age at breast cancer diagnosis N Proportion N Proportion
Below 30 14 3.17% 3 8.57%
30-39 104 23.58% 12 34.29%
40-49 173 39.23% 13 37.14%
50 or above 150 34.01% 7 20.00%
Bilateral cases 84 19.05% 12 34.29%
Histology (Tumors a) 525 100% 47 100%
Ductal 316 60.19% 30 63.83%
Lobular 18 3.43% 0 -
Medullary 7 1.33% 1 2.13%
Ductal + Lobular 2 0.38% 0 -
Ductal + Medullary 1 0.19% 0 -
DCIS 83 15.81% 8 17.02%
Others 27 5.14% 1 2.13%
Unclassified 71 13.52% 7 14.89%
Molecular subtypes (Tumors a) 525 100% 47 100%
ER+ 332 63.24% 25 53.19%
ER- 11 2.10% 1 2.13%
HER2+ 44 8.38% 2 4.26%
TNBC 59 11.24% 9 19.15%
Unknown 79 15.05% 10 21.28%
Have both breast and ovarian cancer
Yes 10 2.27% 3 8.57%
No 431 97.73% 32 91.43%
Family history of breast cancer (first- and 
second-degree relatives)
Yes 195 44.22% 21 60.00%
No 246 55.78% 14 40.00%
a Numbers include tumors from patients with bilateral cancers.
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Taiwan and United States. We have identified 2 recurrent 
mutations (BRCA2 c.3109C>T and BRCA2 c.4965delC) 
using the SNaPshot genotyping panel and a novel mutation 
BRCA2 c.3165_3167delinsCC by NGS.
To further test the feasibility and reproducibility of 
the genotyping panel in Chinese emigrants, we additionally 
collected information of BRCA1/2 mutation spectrum from 
overseas collaborating groups. We received data from 84 
Chinese breast cancer patients who had known pathogenic 
BRCA1/2 mutations, which included 63 different types of 
mutations (22 BRCA1 and 41 BRCA2). Consistent with 
our local data, BRCA2 mutation predominance was seen 
in overseas Chinese breast cancer patients. As shown in 
Table 5, only 14 types of mutations were commonly seen 
in Hong Kong and overseas. Our SNaPshot genotyping 
panel covered 9 types of these mutations (3 BRCA1 and 
6 BRCA2) and should be able to pick up 17 out of the 84 
carriers. The most predominant mutations in this overseas 
spectrum were BRCA2 c.5164_5165delAG (n=4), 
c.7379_7382delACAA (n=4) and c.7878G>A (n=4).
DISCUSSION
The genetic diagnosis of inherited breast cancer is 
clinically important in terms of disease management, and 
offering of genetic counseling and preventive strategies for 
family members who are at risk. The spectrum of BRCA 
mutation varies across countries and ethnicities, and the 
prevalence and dominance of BRCA mutation also varies 
among different populations [14, 15]. Even in Mainland 
Table 3: Characteristics of 155 local Chinese ovarian cancer patients screened for BRCA1/2 mutations
155 tested probands 13 mutation carriers
Mean age at diagnosis 44.74 y 53.62 y
Age range 9 – 85 y 37 – 85 y
Age at ovarian cancer diagnosis N Proportion N Proportion
Below 30 18 11.61% 0 -
30-39 20 12.90% 1 7.69%
40-49 68 43.87% 4 30.77%
50 or above 49 31.61% 8 61.54%
Histology
Epithelial 138 89.03% 13 100%
 Serous 36 23.23% 8 61.54%
 Clear cell 24 15.48% 1 7.69%
 Endometroid 50 32.26% 2 15.38%
 Mucinous 16 10.32% 0 -
 Mixed 12 7.74% 2 15.38%
Stromal 4 2.58% 0 -
Germ Cell 4 2.58% 0 -
Others 3 1.94% 0 -
Unclassified 6 3.87% 0 -
Have both breast and ovarian cancer
Yes 9 5.81% 3 23.08%
No 146 94.19% 10 76.92%
Family history of breast or ovarian cancer (first- 
and second-degree relatives)
Yes 38 24.52% 7 53.85%
No 117 75.48% 6 46.15%
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China, there are more than 55 ethnic groups, in which Han, 
Manchu and Uyghur have the largest populations. Few 
studies have identified BRCA mutations in Chinese breast 
cancer patients, and the prevalence was lower than in the 
West [16, 17]. Identification of Chinese-specific BRCA1/2 
founder and recurrent mutations would be beneficial, not 
only to the Hong Kong patients of whom the majority are 
ethnically Chinese, but also to the enormous population in 
Mainland China and those emigrants in Western countries. 
The genetic testing panel was designed specifically for 
Chinese population to achieve better risk assessment and 
preventive measures [18].
It has been reported that BRCA1 c.5589del8 and 
BRCA2 c.3109C>T are the most common recurrent 
mutations in Han Chinese [19], in which BRCA2 
c.3109C>T has been confirmed to be a founder mutation in 
Southern Chinese [13]. It is of great importance to identify 
the prevalence of BRCA1/2 or other high-penetrance genes 
in Chinese population, so that better risk assessment and 
clinical management can be offered to this subset of the 
population. In view of this, our pilot study was carried 
out to assess the prevalence of germline mutation in 
hereditary breast cancers in Hong Kong. Our previous 
results showed that less than 10% of the clinically high 
risk breast cancer patients harbor BRCA1 and BRCA2 
mutations, and importantly, nearly half of the mutations 
were recurrent mutations [2, 13]. In consistent with our 
previous findings, the current mutational screening using 
the SNaPshot genotyping panel was able to pick up 3.52% 
(21/596) of BRCA carriers among the local cohorts, which 
covered 43.75% (21/48) of the identified mutations. 
Furthermore, BRCA1 c.964delG (n=3), c.4372C>T (n=3) 
and BRCA2 c.3109C>T (n=7) were the most common 
mutations identified by the SNaPshot panel in this study 
cohort (Table 4). Besides, there were 27 mutation carriers 
identified by NGS full gene sequencing or MLPA. Of 
these, most of them were novel to our BRCA mutation 
spectrum, and BRCA1 c.2635G>T (n=2) and BRCA2 
c.7133C>G (n=3) were newly identified recurrent 
mutations in Hong Kong cohort. It is expected that more 
recurrent BRCA1/2 mutations will be identified as the 
cohort size increases, understanding the BRCA mutation 
spectrum is important to update and improve the coverage 
of the SNaPshot panel.
One of the limitations of the SNaPshot genotyping 
panel and amplicon-based NGS is that large genomic 
rearrangements in BRCA1/2 genes could be not detected, 
which were reported to comprise up to 7% of all BRCA 
mutations in Asians [20]. Therefore, the incorporation of 
MLPA into BRCA1/2 testing pipeline is necessary. In this 
study, one BRCA1 large deletion (r.5194_5406 del) was 
identified from local breast cancer patient by this method 
(Table 5) with a frequency of 2.08% (1/48) among all 
mutations. Notably, our previous study of a 1,236 high-
risk Chinese HBOC patient cohort also showed 8 out of 
120 identified mutations (6.67%) were large insertions/
deletions [21].
By comparing the mutation spectra with overseas 
countries, BRCA2 predominance is common among 
Chinese patients, which is concordant with the prevalence 
observed in the local cohort and other studies [19]. 
The BRCA1 c.5470_5477delATTGGGCA and BRCA2 
Figure 1: Workflow of BRCA1/2 mutation screening of 596 breast (BrCa) and ovarian cancer (OvCa) patients (local 
cohort) and 79 overseas Chinese breast cancer patients.
Oncotarget7838www.impactjournals.com/oncotarget
Table 4: BRCA1/2 mutations identified in Chinese patients with hereditary breast and ovarian cancer syndrome
Gene No of cases Mutation (HGVS) Amino acid change Gender
Cancer 
type
Family 
history
SNaPshot 
panel
NGS/
MLPA
BRCA1
1 1 c.212+3A>G p.Cys64* F Ovarian No - NGS
2 1 c.220C>T p.Gln74* F Breast No - NGS
3 3 c.964delG p.Ala322Leufs*19 F Breast Yes Yes -
F Ovarian Yes Yes -
F Breast & Ovarian Yes Yes -
4 2 c.2635G>T p.Glu879* F Breast No - NGS
F Ovarian Yes - NGS
5 1 c.3333delA p.Glu1112Asnfs*5 F Ovarian No Yes -
6 1 c.3342_3345delAGAA p.Glu1115* F Breast & Ovarian No Yes -
7 1 c.3756_3759delGTCT p.Ser1253Argfs*10 F Breast No - NGS
8 1 c.4046_4047delinsA p.Thr1349Lysfs*17 F Ovarian Yes - NGS
9 3 c.4372C>T p.Gln1458* F Breast & Ovarian Yes Yes -
F Breast No Yes -
F Breast Yes Yes
10 1 c.5193+1G>A p.Trp1718Ser fs*2 F Breast Yes - NGS
11 1 c.5335delC p.Gln1779Asnfs*14 F Ovarian No - NGS
12 1 c.5406+1_5406+3delGTA p.Asp1778Glyfs*27 F Ovarian Yes Yes -
13 1 r.5194_5406del p.His1732_Thr1802del F Breast & Ovarian No - MLPA
BRCA2
1 1 c.470_474delAGTCA p.Lys157Serfs*24 F Breast Yes - NGS
2 1 c.1244delA p.His415Leufs*15 F Breast Yes - NGS
3 1 c.1688G>A p.Trp563* F Breast Yes - NGS
4 1 c.1855C>T p.Gln619* F Breast Yes - NGS
5 1 c.2595delA p.Glu866Lysfs*8 F Breast Yes Yes -
6 2 c.2808_2811delACAA p.Ala938Profs*21 F Breast Yes Yes -
F Breast Yes Yes -
7 7 c.3109C>T p.Gln1037* F Breast No Yes -
F Breast No Yes -
M Breast Yes Yes -
F Breast Yes Yes -
F Breast Yes Yes -
F Breast Yes Yes -
F Ovarian No Yes -
8 1 c.3760G>T p.Glu1254* F Breast Yes - NGS
(Continued )
Oncotarget7839www.impactjournals.com/oncotarget
Gene No of cases Mutation (HGVS) Amino acid change Gender
Cancer 
type
Family 
history
SNaPshot 
panel
NGS/
MLPA
9 1 c.4440T>G p.Tyr1480* F Breast Yes - NGS
10 1 c.5722_5723delCT p.Leu1908Argfs*2 F Breast No - NGS
11 1 c.5851_5854delAGTT p.Ser1951Trpfs*11 F Breast & Ovarian Yes - NGS
12 1 c.5951_5952delAA p.Lys1984Ilefs*18 F Breast No - NGS
13 3 c.7133C>G p.Ser2378* F Breast Yes - NGS
F Breast No - NGS
F Ovarian No - NGS
14 1 c.7558C>T p.Arg2520* F Breast Yes - NGS
15 1 c.7999delA p.Ser2776Alafs*6 F Breast & Ovarian Yes - NGS
16 1 c.8331+2T>C r.7826_8331del506 F Breast Yes - NGS
17 1 c.8488-9T>G p.Trp2830Tyrfs*36 F Breast Yes - NGS
18 2 c.9294C>G p.Tyr3098* F Breast Yes Yes -
F Breast No Yes -
19 1 c.9409dupA p.Thr3137Asnfs*13 F Breast No - NGS
20 1 c.10150C>T p.Arg3384* F Ovarian Yes - NGS
Table 5: BRCA1/2 mutations that seen in both Hong Kong and overseas spectrums
Gene Mutation (HGVS) Amino acid change Covered by SNaPshot genotyping panel
BRCA1 c.470_471delCT p.Ser157* Yes
c.3607C>T p.Arg1203* No
c.4148C>G p.Ser1383* Yes
BRCA2 c.755delA p.Asp252Alafs*25 No
c.2808_2811delACAA p.Ala938Profs*21 Yes
c.5164_5165delAG p.Ser1722Tyrfs*4 Yes
c.5238dupT p.Asn1747* No
c.7007G>T p.Gly2313Alafs*31 Yes
c.7133C>G p.Ser2378* No
c.7409dupT p.Thr2471Hisfs*4 No
c.7558C>T p.Arg2520* No
c.7878G>A p.Trp2626* Yes
c.9097dupA p.Thr3033Asnfs*11 Yes
c.9393delC p.Lys3132Asnfs*31 No
Note: BRCA1 c.5470_5477del8 and BRCA2 c.4965delC were not seen in the Hong Kong cohort, but were covered by the 
SNaPshot genotyping panel.
c.7878G>A were the most prevalent mutations among 
Chinese breast cancer patients that reside in US and 
other countries. The frequencies of BRCA mutations 
were 10.5% from a cohort of 409 Chinese breast cancer 
patients in Northern China, and BRCA2 mutations were 
more common than BRCA1 [22]. Large-scale population 
screening is warranted to unravel the frequencies and 
penetrance of BRCA mutations in Chinese population.
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Identification and molecular diagnosis of HBOC 
families allow healthcare providers and professionals to 
decide on the clinical management guidelines and strategies. 
Substantial data from the West pointed to the importance of 
mutation screening and counselling [23], however, access to 
genetic services including genetic counselling in Mainland 
China is still inadequate. The cost of genetic testing and 
lack of coverage by local healthcare system are the main 
obstacles for mutation screening in Hong Kong and many 
parts of Asia [14]. Although next-generation sequencing 
is getting popular in the field of mutation screening, its 
high setup costs and the requirements of bioinformatics 
pipeline and sequencing data analysis are still challenging. 
Therefore, development of a genotyping panel for targeted 
recurrent mutation screening can offer a simple, rapid 
and affordable routine molecular diagnostic method that 
is feasible in most diagnostic laboratories. In our genetic 
testing workflow, initial screening using SNaPshot 
genotyping panel costs about USD 50 per sample with a 
turn-around time of 3 days, while the BRCA1/2 full-gene 
sequencing with NGS cost about USD 1,500 per sample.
Data from this present study demonstrated around 
10% of Chinese HBOC families had BRCA mutations 
which emphasizes the significant impact on breast 
cancer and ovarian cancer risk in the local population. 
Implementation of the SNaPshot genotyping panel in 
the mutation screening pipeline is feasible which helps 
to identify patients who are at risk, and may change the 
paradigm for treatment in this subset of patients who carry 
BRCA mutation.
MATERIALS AND METHODS
Patients and DNA samples
441 high-risk breast cancer probands and 155 
unselected ovarian cancer probands were recruited by Hong 
Kong Hereditary and High Risk Breast Cancer Programme 
(HRBCP) in Queen Mary Hospital and Tung Wah Hospital 
in Hong Kong. In addition, 79 overseas Chinese with breast 
and/or ovarian cancers were recruited from Australia, 
Taiwan and the United States. Written informed consent 
was obtained from all participating patients, and this 
study was approved by the Institutional Review Board 
(IRB) of The University of Hong Kong, and Hospital 
Authority Hong Kong West Cluster. Patient information 
including age, family history, and clinical reports were 
recorded (Tables 2 and 3). Genomic DNA was extracted 
from peripheral blood for BRCA1/2 genetic testing using 
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) 
according to the manufacturer's instructions.
Genetic testing selection criteria
High-risk breast cancer patients were recruited if 
any of the following criteria were met: (1) diagnosis of 
breast cancer at age ≤ 45 years; (2) bilateral breast cancer; 
(3) triple-negative or medullary type pathology; (4) male 
breast cancer; (5) at least one first- or second- degree 
relative with breast and/or ovarian cancer, regardless of 
age. In the unselected cohort of ovarian cancer, patients 
who had ovarian, fallopian tube or peritoneal cancer at any 
age were recruited.
Genetic testing workflow
Recruited breast and ovarian cancer probands 
were first tested for the 25 targeted BRCA1/2 recurrent 
mutations using the SNaPshot genotyping panel (Table 1). 
Those who tested negative were assayed for large genomic 
rearrangements by MLPA and amplicon-based NGS 
targeting all BRCA1/2 exons [2]. All mutations identified 
by the SNaPshot genotyping panel and NGS were further 
verified by independent Sanger sequencing. The genetic 
testing workflow was illustrated in Figure 1.
Mutation screening by single base extension 
(SBE) assay (SNaPshot)
Twenty-five BRCA1/2 mutations, including 
founder and recurrent mutations reported in Chinese 
ethnic groups, were identified by our group [13] 
or from literature search [12, 22, 24, 25] (Table 1). 
These mutations were reported in China, Hong Kong, 
Malaysia and Singapore Chinese populations, and were 
all small insertion/deletion or nonsense mutations. 
Primers designed for PCR amplification and SNaPshot 
genotyping assays (Applied Biosystems, Thermo Fisher 
Scientific, MA, USA) were listed in Supplementary 
Tables 1 and 2. The single base extension assay, 
SNaPshot, has been adopted for mutation screening. 
In brief, all 25 mutation loci were amplified by 
multiplex PCR. The mutations were examined by 
primers positioned immediately 5’ to the heterozygous 
bases. Single base extension reaction was performed in 
multiplex using the SNaPshot kit and modified primers 
with linkers of different repeating units of oligo TGAC. 
After purification, the SNaPshot products were run with 
120 LIZ size standard in sequencing analyzer e.g. ABI 
Prism 3730. Data were processed by Genescan Analysis 
(Applied Biosystems). Relative intensity of the two 
alleles in each sample was calculated and confirmed the 
heterozygosity. The signal from the normal control DNA 
was used as reference.
Next-generation sequencing (NGS)
Samples tested negative from the SNaPshot 
genotyping panel were further assayed for BRCA1/2 full-
gene sequencing by NGS. The Fluidigm Access Array 
System (Fluidigm, San Francisco, USA) was used to 
generate separate pools of 74 PCR amplicons per sample 
for targeting all exons of the BRCA genes plus 10 bp from 
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intron-exon boundaries as previously described [26]. 768 
barcode combinations were used in rotation to minimize 
using the same combination in two consecutive runs. 
Paired-end sequencing of the amplicons (2 x 300bp) was 
performed on a MiSeq (Illumina, San Diego, USA) with 
reagent kit v3.
Sequences obtained from each sample were mapped 
to human genome reference GRCh37/hg19 using BWA-
MEM version 0.7.7 with default parameters [27]. The 
minimum sequencing depth of coverage for ROI was 
100x. Two variant callers were used: (1) Samtools version 
0.1.9 [28], with mpileup command parameters -L 100000 
-d 100000 to cater for amplicons with depth exceeding 
250-fold and bcftools command parameter –m0.99 to use 
the new insertion-deletion (INDEL) calling model; (2) 
GATK HaplotypeCaller version 2.8-1 [29] according to 
the best practices as mentioned previously [2]. Variant 
calls were annotated by Ensembl Variant Effect Predictor 
version 75 [30]. The bioinformatic analysis was performed 
on a Cray XC30 supercomputer (Cray, Seattle, USA). 
Pathogenic mutations or ROI positions with depth of 
coverage below 100x were subject to Sanger sequencing 
and data analysis by Mutation Surveyor version 4.0.6 
(Softgenetics Inc, USA).
BRCA mutation validation by DNA sequencing
All BRCA mutations identified from SNaPshot 
genotyping panel and NGS were further validated by 
Sanger sequencing. Sequencing results were compared 
with the reference DNA sequences using Variant Reporter 
software (Applied Biosystems) and then reviewed 
manually. Computational analysis for potential cryptic 
splice site mutations were performed using splice site 
prediction programs such as NNSPLICE and ESEF 
finder. All mutations were named according to the 
recommendations from Human Genome Variation Society 
(HGVS). Variant descriptions were checked by Mutalyzer 
Name Checker (http://mutalyzer.nl). DNA sequencing 
was supplemented by multiplex ligation dependent 
probe amplification (MLPA) to detect large deletions or 
rearrangements [21, 31].
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